Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 23Neutropenia 22Neoplasms 7Chemotherapy-induced Neutropenia 7Lymphoma, Non-Hodgkin 6Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Lymphoma 3Fever 3Febrile Neutropenia 3Colorectal Neoplasms 3Rectal Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Neuroectodermal Tumors, Primitive, Peripheral 1Malignant Solid Tumors 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myeloid, Acute 1

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Malignant Solid Tumors × pegfilgrastim × Clear all
NCT02805166 2016-06-17

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 4 Completed
420 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡